Menarini Stemline’s Post

Delighted to share this short video clip discussing secondary malignancy rates in CAR-T treated patients which, Sheila and Penelope my Data Science colleagues at Medidata, will be presenting at #ASH24. This is a nice example of the types of robust clinical insights/re-affirmations of putative findings that can be gained by pooling data from many clinical trials, or by using Medidata's "Simulants" data (high-fidelity, privacy-preserving synthetic data that Medidata generates using its proprietary algorithms on pooled clinical trial data to enable robust insights from increased sample size and corresponding study power). Please feel free to share with others in your professional network, and reach out if you would like to learn more about Medidata's "Simulants" data and the types of clinically useful insights that can be extracted to inform clinical development plans/decisions or aid in clinical trial designs.

This weekend, a small piece of my work in the CHIVE and IMPACT programs, will be presented at the American Society of Hematology annual meeting in San Diego. This work provides a blueprint on delivering clinical trial access to underserved areas, while also providing contributions to Clonal Hematopoiesis (CH) research. We hope to expand this work to additional clinics, especially those in underserved areas. We also hope our research can contribute to the development of additional clinical trials for high-risk CH and to refining care protocols for CH. https://lnkd.in/eHTeUyyT

🙋🏻♂️ The European Hematology Association (EHA) Congress started today. It is interesting to see the number of sessions dedicated to patient centricity. Patient perspective is essential for understanding their experience along the disease journey. #EHA2024 #patientcentricity #patientadvocacy

Weekend biotech fun. If in case, you missed promising BEAM-101 clinical data in patients with sickle cell disease (SCD). BEAM-101 is an autologous genetically modified cell therapy. An autologous therapy means that the cells themselves are taken from an individual's own tissues, cells, or DNA. These cells are extracted, edited outside the patient’s body & later restored to help fight SCD.

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

Register using the link below to join our webcast tonight at 9:00pm EST / 6:00pm PST to hear more about the progress shared today on DISC-0974 at #ASH24 and plans for next steps in development #Anemia in #Myelofibrosis. #DiscMedicine

The revolutionary breakthroughs that transform healthcare can seem like magic. But pioneering research is grounded in evidence, experimentation and endless evaluation. At Regeneron, we believe spellbinding science happens when curiosity drives innovation. Hear more from Lorah Perlee, VP, Hematology Global Program Head, on how we hope to reshape our understanding of what’s possible in hematology. #ASH2024 🧪✨🔬 https://bit.ly/3Bk7t8S

ConcertAI and NeoGenomics Laboratories are excited announce CTO-H, a joint data-as-a-service and software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization! CTO-H provides a research data solution that is unprecedented in its scale, longitudinality, and biomarker depth. This announcement is a major outcome of the collaboration jointly announced on Jan. 8, 2024 – hear more at the 2024 American Society of Hematology (ASH) Meeting in San Diego. Read more: https://hubs.ly/Q02-w76R0 Meet with us at ASH 2024: https://hubs.ly/Q02-LFb30 #HematologyInnovation #AIinHealthcare #ClinicalTrials #OncologyData #ASH24

#GenoMed4All and Synthema represented at this year's #ASCAT conference thanks to ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases) 🩸🤝 Healthcare professionals, researchers and patient groups have gathered this week at the 19th Annual Scientific Conference in London, hosted by the Academy For Sickle Cell & Thalassaemia (ASCAT) in collaboration with British Society for Haematology and European Hematology Association (EHA). The aim? To explore the latest breakthroughs in haemoglobinopathies (#BloodDisorders) and discuss the new advancements in diagnosis, treatment and emerging therapies for #SickleCellDisease and #Thalassemia. During the Patient Session on the 2nd day of the conference, Mariangela Pellegrini from ERN-EuroBloodNet highlighted the work we've been doing collaboratively with them and our sister project #Synthema to advance #PrecisionMedicine for #SCD 🦾🏥 Find out more ➡️ https://lnkd.in/dQhdMGN4

Attending ASH 2024, seeing first-hand the major scientific advances that are changing how multiple myeloma is treated and managed has been a truly inspiring experience. The progress we are witnessing is shifting the paradigm towards functional cure and the potential for a normal life expectancy.  The outlook for patients and the medical community is brighter than ever. However, with innovation comes new challenges, particularly in selecting the optimal approach. Transitioning from generalised treatments marked by cycles of remission and relapse, we are embracing personalised strategies across the care pathway. This means:  💡 Prioritising the best treatment first, where it can deliver the greatest impact on patient outcomes  💡 Enhancing, and prioritising patient experience by optimising regimens for improved tolerability, convenience and accessibility, looking not only at prolonging life but also providing a good quality of life  💡 Considering patient preferences and discussing treatment goals as part of shared decision-making  My colleague, Edmond K. Chan, captured what it was like to be at ASH hearing about these important updates. Take a look.   #ASH24 #InFrontOfCancer #mycompany